罗氟司特中国上市了吗？

Roflumilast was first developed in 1993 by Altana (acquired by Swiss Nycomed in 2007) and launched by Swiss Nycomed (acquired by Takeda in 2011). Roflumilast is an oral selective phosphodiesterase 4 (PDE4) inhibitor. In July 2010, the European Union approved it for severe chronic obstructive pulmonary disease (COPD). It was first marketed in Germany and the United Kingdom. In February 2011, roflumilast was launched in the United States under the trade name Daliresp. The dosage form is film-coated tablets with a specification of 0.5 mg. Currently, it is in phase III clinical stage in Japan and has not yet been launched.

As a new drug for the treatment of COPD, roflumilast is an inhibitor called phosphodiesterase-4 (PDE-4). It is used to treat cough and mucus excess in severe COPD patients with bronchitis. Roflumilast is not used to treat other types of COPD such as primary emphysema. Roflumilast can improve mucociliary clearance by increasing the activity of cystic fibrosis transmembrane transport regulators in bronchial epithelium.

In addition, roflumilast can inhibit the levels of centrocyte elastase and MMP-9, thereby correcting the imbalance of proteases and anti-proteases in COPD patients, inhibiting the chemotaxis and proliferation of fibroblasts, thereby reversing airway remodeling and improving lung function.

Is it listed in China? Currently, roflumilast is not marketed in China and is not eligible for medical insurance. In other words, if patients want to purchase the drug, they must go abroad to purchase it. Traveling abroad to buy medicines is a long journey and requires a lot of manpower and material resources. Coupled with the huge medical expenses, many patient families are overwhelmed. However, according to Medical Companion Travel, 500μg*90 tablets of roflumilast costs approximately $2,850 per box. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about roflumilast, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.